Get started
Author

Kristian Shtembari

Observed name: K. Shtembari
OpenAlex ID: A5117723305
Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
2025 · Martina Catalano, Gestiana Cekrezi, et al. · Cancer Chemotherapy and Pharmacology · 4
PDF
Immune Checkpoint Inhibitor-Related Pneumonitis in Renal Cell Carcinoma: Clinical Features, Mechanisms, and Lessons from Lung Cancer
2026 · Kristian Shtembari, Martina Catalano, et al. · Biomolecules · 2
PDF
Impact of relative dose intensity (RDI) of perioperative FLOT in resectable and locally advanced gastric and gastroesophageal junction adenocarcinoma.
2025 · Giulia Massaro, Daniele Lavacchi, et al. · Journal of Clinical Oncology · 2
PDF
The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors
2026 · Alexandra Paulet, Silvia Mancini, et al. · Anti-Cancer Drugs · 1
Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies
2026 · Giandomenico Roviello, Kristian Shtembari, et al. · Expert Review of Anticancer Therapy
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology
2026 · Martina Izzi, Kristian Shtembari, et al. · Future Oncology
Oligoprogressive Prostate Cancer: Can Metastasis-Directed Therapy Prolong the Benefit of Systemic Treatment?
2026 · Giandomenico Roviello, Kristian Shtembari, et al. · Clinical Genitourinary Cancer
PDF
Predictive biomarkers in cancer immunotherapy for genitourinary malignancies
2026 · Alexandra Paulet, Kristian Shtembari, et al. · Critical Reviews in Oncology/Hematology
PDF
563eP The good, the bad, and the manageable: Real-world outcomes with CDK4/6 inhibitors
2026 · A. Paulet, S. Mancini, et al. · ESMO Open
A new multimodal approach: chemoimmunotherapy followed by chemoradiation therapy and pembrolizumab maintenance
2026 · Roberta Renda, Kristian Shtembari, et al. · International Journal of Gynecological Cancer
2155P Real-world outcomes of relative dose intensity (RDI) of FLOT in gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: A multicenter retrospective Italian study
2025 · G. Massaro, A. Paulet, et al. · Annals of Oncology
375eP Biliary stenting in biliopancreatic tumors: Evidence from real-world practice
2025 · L. Pratesi, V.M. Gangi, et al. · Annals of Oncology
PDF
Works count: 12
Citation count: 9
H-index: 2
I10-index:
Year
Topic
Type